Phase 2 trial of oral S-1 combined with low-dose cisplatin for unresectable advanced pancreatic cancer.

Abstract

OBJECTIVES:

A phase 2 trial of S-1 combined with cisplatin was conducted for unresectable pancreatic cancer.

PATIENTS AND METHODS:

S-1 was administered for 28 days followed by a rest of 14 days. Cisplatin was infused on days 1-5, 8-12, 15-19 and 22-26 of the first course. After the second course, S-1 was administered as maintenance chemotherapy.

RESULTS:

Thirty patients were enrolled and the responses observed were 0 complete response, 5 partial response, 22 stable disease and 3 progressive disease, with an overall response rate of 17% (95% confidence internal (CI), 6-35%). Toxicity was tolerable, with grade 3 toxicities observed for leukocytopenia (10%), neutropenia (7%), anemia (3%), thrombocytopenia (3%), anorexia (13%), and nausea and vomiting (7%). The median survival time (MST) and the 1-year survival rate were 9.0 months (95% CI, 6.0-14.5 months) and 35.7% (95% CI, 19-55%), respectively.

CONCLUSION:

S-1 with low-dose cisplatin is well tolerated and effective for advanced pancreatic cancer.

• Authors: Shinomi Ina, Masaji Tani, Manabu Kawai, Seiko Hirono, Motoki Miyazawa, Ryohei Nishioka, Yoichi Fujita, Hiroki Yamaue
• Journal: Anticancer research (Anticancer Res) 2008 Jul-Aug Vol. 28 Issue 4C Pg. 2373-7 ISSN: 0250-7005 [Print] Greece
• PMID: 18751421 (Publication Type: Clinical Trial, Phase II, Journal Article)

Chemical References

• Drug Combinations
• S 1 (combination)
• Tegafur
• Oxonic Acid
• Cisplatin

Topics

• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Cisplatin (administration & dosage, adverse effects)
• Dose-Response Relationship, Drug
• Drug Combinations
• Female
• Humans
• Male
• Middle Aged
• Oxonic Acid (administration & dosage, adverse effects)
• Pancreatic Neoplasms (drug therapy)
• Survival Rate
• Tegafur (administration & dosage, adverse effects)